Vertical Pharmaceuticals, LLC
$60.9K 2,949 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Perrigo Company plc
Perrigo Company plc reported $60,828.60 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 13 transactions.
- $60.8K Below-median payer
- All-tracks total
- 13 Below-median volume
- Transactions
- 12 Below-median reach
- Recipients
- −$16.6K
- General Payments vs PY2023
Perrigo Company plc reported $60,828.60 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #1306 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $55,828.60, averaging $5.1K per recipient.
How Perrigo Company plc's $60.8K all-tracks total breaks down
Perrigo Company plc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer perrigo-company-plc Perrigo Company plc
$60.8K · #1306/1,925 · 0.0% industry · PY2024
- TOT $60.8K
- RANK #1306
- SHARE 0.0%
- TXN 13
- RCP 12
- CAT 3
- GEN $55.8K
- ΔGEN −$16.6K
- TOP1 31.8%
- PY 2024
Volume peers
Nearest volume peer: Vertical Pharmaceuticals, LLC ($60.9K)
Perrigo Company plc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Perrigo Company plc's CMS-reported General Payments decreased by $16.6K (−22.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PERRIGO COMPANY PLCPY2023: PERRIGO COMPANY PLCPY2024: Perrigo Company plc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $72,390.00
- PY2024
- $55,828.60
What the Data Shows for Perrigo Company plc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Perrigo Company plc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Compensation for Services Other Than Consulting" leads the 3-category general-payment breakdown below at $49.5K (88.7% of General Payments, 9 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Perrigo Company plc's 3-category general-payment breakdown at $49.5K, 88.7% of the reported total.
How Perrigo Company plc divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $49.5K | 9 | 88.7% |
| Consulting Fee | $5.0K | 1 | 9.0% |
| Travel and Lodging | $1.3K | 2 | 2.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $54,973.60 (98.5%) of $55,828.60 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Perrigo Company plc
The five named recipients with the highest reported General Payments from this company
- 1
Franziska Hasselhof
$17,750.00 across 3 reported transactions
- 2
Ashanda Saint Jean
$14,123.60 across 4 reported transactions
- 3
Taylore Passero
$12,350.00 across 1 reported transactions
- 4
Jessica Shepherd
$5,750.00 across 1 reported transactions
- 5
Lisa Rarick
$5,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Perrigo Company plc ranks #1306 of 1,925 by total payments (bottom 32% by spend) but is notably more concentrated than that alone would suggest -- #688 of 1,838 by HHI (top 37% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Human Regenerative Technologies : $64.8K total payments, HHI 2346
- Medical Microinstruments, Inc. : $113.0K total payments, HHI 2343
- Captiox LLC : $34.7K total payments, HHI 2342
- Visby Medical, Inc. : $73.4K total payments, HHI 2338
- RIWOspine, Inc. : $30.8K total payments, HHI 2333
- HAPPE Spine : $1.2K total payments, HHI 2328
- Perrigo Company plc (this company) : $55.8K total payments, HHI 2328
- Microline Surgical Inc : $45.6K total payments, HHI 2322
- Lazurite Inc. : $20.5K total payments, HHI 2322
- Canon Healthcare USA, Inc. : $5.3K total payments, HHI 2317
- LENSAR, Inc. : $330.1K total payments, HHI 2312
- Astellas Pharma Inc : $82.8K total payments, HHI 2312
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Perrigo Company plc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Perrigo Company plc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Perrigo Company plc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ovesco Endoscopy USA, Inc.
$61.0K 62 recipients
Compare payment profiles
Lenoss Medical Inc
$61.1K 50 recipients
Compare payment profiles
Forma Medical
$61.1K 76 recipients
Compare payment profiles
Clarius Mobile Health Corp.
$60.4K 27 recipients
Compare payment profiles
Spirair, Inc.
$60.4K 219 recipients
Compare payment profiles
Put this to use
Perrigo Company plc ranks #1306 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Perrigo Company plc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.